Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

Pitmaster23 Aug. 1 at 1:59 AM

$VTGN waiting for re-entry. Neuro biotech scares me. Strong placebo effects can skew results.

0 · Reply

Stockrunner54 Jul. 31 at 6:09 PM

$VTGN u have to be retarded to short one of the most volatile and explosive biotechs in the market.

0 · Reply

kimgysen Jul. 31 at 5:37 PM

$VTGN That looks nasty

1 · Reply

Haimalon Jul. 31 at 5:35 PM

$VTGN It looks like die hard , shorts are playing slowly to reduced the price

0 · Reply

MoffaMan Jul. 31 at 5:13 PM

$VTGN additional dilution will be announced on Aug 7th

1 · Reply

StockHunter75 Jul. 31 at 4:49 PM

$VTGN

0 · Reply

Stockrunner54 Jul. 31 at 1:19 PM

$VTGN email alert: Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

0 · Reply

Haimalon Jul. 31 at 11:42 AM

$VTGN No news from the BTIG conference , as any one heard something or know where we can hear the conference?

0 · Reply

RemoteInvestor Jul. 31 at 4:56 AM

$VTGN evey minute, every hour counts... Readout in 2025!

0 · Reply

MakesHerSquirt Jul. 30 at 10:28 PM

$VTGN Very volatile from here on out. I suck but this is the way.

0 · Reply

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 24, 2025, 8:30 AM EDT - 7 days ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 16 days ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 5 weeks ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 6:49 PM EDT - 6 weeks ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 4:30 PM EDT - 6 weeks ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 7 weeks ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 2, 2025, 8:30 AM EDT - 2 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

May 28, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 23, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Apr 17, 2025, 8:30 AM EDT - 3 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Mar 19, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 4, 2025, 8:30 AM EST - 5 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Feb 20, 2025, 8:30 AM EST - 5 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 6:19 PM EST - 5 months ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 13, 2025, 8:47 PM EST - 6 months ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 4:30 PM EST - 6 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 6 months ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 6 months ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Jan 14, 2025, 8:30 AM EST - 7 months ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 10, 2025, 8:30 AM EST - 7 months ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Nov 14, 2024, 8:30 AM EST - 9 months ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 10, 2024, 7:43 AM EST - 9 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 4:20 PM EST - 9 months ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 5, 2024, 8:30 AM EST - 9 months ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 1, 2024, 8:30 AM EDT - 9 months ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Oct 15, 2024, 7:25 AM EDT - 10 months ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 9, 2024, 8:30 AM EDT - 10 months ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Sep 23, 2024, 8:30 AM EDT - 11 months ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Aug 13, 2024, 7:05 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 4:21 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 11, 2024, 6:41 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 4:20 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Jun 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

May 29, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Mar 20, 2024, 9:01 PM EDT - 1 year ago

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

Mar 17, 2024, 3:07 AM EDT - 1 year ago

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY BTMD DARE

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at Stifel 2024 Virtual CNS Days

Feb 28, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

Feb 13, 2024, 6:34 PM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript

Feb 13, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Pitmaster23 Aug. 1 at 1:59 AM

$VTGN waiting for re-entry. Neuro biotech scares me. Strong placebo effects can skew results.

0 · Reply

Stockrunner54 Jul. 31 at 6:09 PM

$VTGN u have to be retarded to short one of the most volatile and explosive biotechs in the market.

0 · Reply

kimgysen Jul. 31 at 5:37 PM

$VTGN That looks nasty

1 · Reply

Haimalon Jul. 31 at 5:35 PM

$VTGN It looks like die hard , shorts are playing slowly to reduced the price

0 · Reply

MoffaMan Jul. 31 at 5:13 PM

$VTGN additional dilution will be announced on Aug 7th

1 · Reply

StockHunter75 Jul. 31 at 4:49 PM

$VTGN

0 · Reply

Stockrunner54 Jul. 31 at 1:19 PM

$VTGN email alert: Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

0 · Reply

Haimalon Jul. 31 at 11:42 AM

$VTGN No news from the BTIG conference , as any one heard something or know where we can hear the conference?

0 · Reply

RemoteInvestor Jul. 31 at 4:56 AM

$VTGN evey minute, every hour counts... Readout in 2025!

0 · Reply

MakesHerSquirt Jul. 30 at 10:28 PM

$VTGN Very volatile from here on out. I suck but this is the way.

0 · Reply

Gabriel_DS Jul. 30 at 6:34 PM

$VTGN

0 · Reply

gramirez Jul. 30 at 2:20 PM

$VTGN take my money!!!

0 · Reply

gramirez Jul. 30 at 2:19 PM

$TYGO Solid performance all around! $VTGN is nearing a big moment with its treatment. 🧬

0 · Reply

gramirez Jul. 30 at 2:18 PM

$REPL Strong numbers today. $VTGN could be the next big biotech winner with Fasedienol. 💥

0 · Reply

Konggugkmull Jul. 30 at 10:29 AM

$VTGN Today will be

1 · Reply

Haimalon Jul. 30 at 9:48 AM

$VTGN The real question today is red or green

0 · Reply

Apalom198 Jul. 29 at 7:15 PM

$VTGN Oh, that was your big warning? A 2% pullback after a 90% rally? 🤡 You must be new here. Real traders don’t scream ‘bearish’ every time a stock exhales. You didn’t call anything — you just wanted to be heard. Next time, let the adults talk.

1 · Reply

Haimalon Jul. 29 at 6:43 PM

$VTGN So nothing from the BTIG , its very strange ???

0 · Reply

Stockrunner54 Jul. 29 at 4:39 PM

$VTGN might be getting some Jerome Powell effect today… I think I’m getting tired of that guy. Get rid of him.

1 · Reply

Haimalon Jul. 29 at 3:59 PM

$VTGN any news from the BTIG ?

0 · Reply

Stockrunner54 Jul. 29 at 3:08 PM

$VTGN some wishing they could load cheap again, not gonna happen !

0 · Reply

Haimalon Jul. 29 at 2:56 PM

$VTGN Today it will close green

0 · Reply

Market Cap	86.02M
Revenue (ttm)	490,000.00
Net Income (ttm)	-51.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,493.88%
Debt to Equity Ratio	0.00

Volume	372,300
Avg Vol	310,168
Day's Range	N/A - N/A
Shares Out	29.16M
Stochastic %K	45%
Beta	0.61
Analysts	Strong Sell
Price Target	$13.00